Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from MBX Biosciences, Inc. ( (MBX) ) is now available.
On September 24, 2025, MBX Biosciences, Inc. entered into an Underwriting Agreement with J.P. Morgan Securities LLC and Jefferies LLC for a public offering of 11,108,055 shares of common stock at $18.00 per share, closing on September 26, 2025. The company raised approximately $187.5 million from the offering, which will be used to advance its clinical-stage programs, fund research and development activities, and for general corporate purposes.
The most recent analyst rating on (MBX) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Underperform.
MBX Biosciences faces significant challenges with its zero revenue and increasing losses, heavily impacting financial performance. Bearish technical indicators and valuation concerns compound the risks. While the strategic board appointment is a positive step, it does not offset the primary financial and operational difficulties.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
Average Trading Volume: 1,039,491
Technical Sentiment Signal: Strong Buy
Current Market Cap: $675.5M
See more insights into MBX stock on TipRanks’ Stock Analysis page.